P-134 Incidence of radiation pneumonitis in lung cancer patients with idiopathic pulmonary fibrosis = P-134 Incidence of radiation pneumonitis in lung cancer patients with idiopathic pulmonary fibrosis

다국어 초록 (Multilingual Abstract)

Background: Idiopathic pulmonary fibrosis (IPF) is well known to affect the prognosis of lung cancer. The goal of this study was to evaluate the incidence of radiation pneumonitis after radiotherapy in lung cancer patients with IPF and compare it to those without IPF.
Methods: We retrospectively reviewed medical records of patients who had received radiation therapy on lung cancer in 2 tertiary university hospitals from 2004 to 2014. We excluded patients treated with palliative radiotherapy or SABR (Stereotactic ablative radiotherapy).
Results: During the period, total 1445 patients underwent radiation therapy for lung cancer. Among them, 53 patients had IPF when they had been diagnosed with lung cancer. We selected 2 matched controls (matched by lung cancer stage, histopathology, and sex) for each patient with IPF. Baseline characteristics, ECOG, middle or lower location of lung cancer, stage, pathology, total radiation dose were not different significantly between two groups. Radiation pneumonitis developed in 30/53 (60%) in IPF patients and 54/94 (57.4%) in patients without IPF (p=0.767). Among those with radiation pneumonitis, more than grade 2 radiation pneumonitis was more prevalent in IPF patients (48.3%) than in non-IPF patients (9.6%, p-value 0.001).
Conclusion: The incidence of radiation pneumonitis in lung cancer patients with IPF was similar to that in those without IPF. On the other hands, more than grade 2 radiation pneumonitis treated with steroid or oxygen was more prevalent in lung cancer patients with IPF than those without IPF.